Abrdn Life Sciences Investors (HQL:NYSE) closed at $17.73 on October 23, 2026, down 1.23% on the day. The stock trades 21.8% below its 52-week high of $22.67 and 13.2% above its 52-week low of $15.66. Over the past year, it gained 5.4%. Abrdn Life Sciences Investors is part of the Miscellaneous sector.
In 252 trading sessions since October 23, 2025, HQL closed higher on 126 days (50%). Its best day was October 20, 2026 (+4.46%) and its worst was October 13, 2026 (-4.11%). It never moved 10% or more in a single session.
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Find more stocks like HQL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.